More recently, PARP inhibitors (PARPi) have become a critical addition to the treatment of metastatic castration resistant prostate cancer (mCRPC) where, unlike breast and ovarian cancer, ~50% of BRCA mutations occur in the absence of an inherited germline mutation. Here, PARP1 is linked to ovarian cancer.